An Update on the Leading COVID-19 Vaccines

Ahmed Eladely1, MBBCh; Javaria Anwer1, MBBS; Ashwini Gotimukul1, MBBS; Manish KC1, MBBS; Jessica Petrey2, MSLS; Alex Glynn1, MA; Ruth Carrico1, PhD DNP; Julio A. Ramirez1*, MD

1 Center of Excellence for Research in Infectious Diseases, Division of Infectious Diseases, University of Louisville, Louisville, KY, USA; 2Kornhauser Sciences Library, School of Medicine, University of Louisville, Louisville, KY, USA

*j.ramirez@louisville.edu

Recommended Citation: Eladely A, Anwer J, Gotimukul A, et al. An update on the leading COVID-19 vaccines. Univ Louisville J Respir Infect 2021; 5(1): Article 2.

Abstract

We reviewed the COVID-19 vaccines that reached phase III of clinical development. For each of the 10 vaccines identified, we described the technology used for vaccine development, the available data from phase III clinical trials, data on vaccine safety, and the role of new SARS-CoV-2 variants on vaccine efficacy.

Introduction

There are exceptional ongoing efforts to develop effective vaccines against SARS-CoV-2 with the goal to control the current COVID-19 pandemic. According to the World Health organization, as of March 1, 2021, there are 182 vaccines in preclinical development and 74 vaccines in different phases of clinical development.[1] We performed a literature review with the objective to evaluate the vaccine efficacy, safety and technology of the COVID-19 vaccines that have reached phase III of clinical development.

Methods

Vaccines that reached phase III of clinical development

COVID-19 vaccines that had reached phase III of clinical development were identified. These vaccines were classified in two groups: the vaccines that completed phase III studies (no longer recruiting participants), and the vaccines in ongoing phase III studies (still recruiting participants). These groups were further classified according to the quality of the data currently available to review the efficacy and safety of each vaccine. Priority was given to data obtained from studies published in peer-reviewed journals, followed by data obtained from press release documents.

Vaccine technology

For each of the vaccines that reached phase III clinical trials, the technology used for the development of the vaccine was identified. These technologies fall into two categories: protein-based vaccines, used to inject participants with SARS-CoV-2 proteins; and gene-based vaccines, used to inject participants with SARS-CoV-2 genetic material.

Vaccine phase III clinical trial data

The data from phase III clinical trials were summarized for vaccines with data available from peer-reviewed publications and vaccines with only press-released data. The vaccines were ordered according to the number of COVID-19 cases used to calculate their efficacy, prioritizing studies with a greater number of COVID-19 cases. We also evaluated the generalizability of their respective study data, as determined by the number of study subjects and the number of countries participating in the trial.

Vaccine safety data

Data concerning the safety of the vaccines were obtained from peer-reviewed publications as well as press release documents.

Vaccine efficacy and SARS-CoV-2 variants

A review of peer-reviewed publications was performed to evaluate vaccine efficacy in relation to emergent

ULIRI | https://ir.library.louisville.edu/jri/vol5/iss1/2
Figure 1. Vaccines that reached phase III of clinical development.

Figure 2. Phase III vaccines categorized by technology.
SARS-CoV-2 variants.

Results

Vaccines that reached phase III of clinical development

We identified 10 vaccines that reached phase III of clinical development. The classification of these 10 vaccines according to phase III clinical trial status—completed or ongoing—and availability of clinical trial data are depicted in Figure 1.

Vaccine Technology

The technology used in the development of these 10 vaccines is described in Table 1. We identified three vaccines with phase III clinical trial data from press release documents. The review of the available data for these vaccines is described in Table 2.

Vaccine phase III clinical trial data

Four vaccines have completed phase III clinical trials with data available in peer-reviewed journals. Our review of the data from these clinical trials in relation to vaccine efficacy, number of trial participants, number of cases of COVID-19, and location of trial sites is described in Table 1. We identified three vaccines with phase III clinical trial data from press release documents. The review of the available data for these vaccines is described in Table 2.

Vaccine safety data

Some recipients of the vaccines under discussion have reported mild to moderate adverse events. Local adverse events include pain at injection site, erythema, pruritus and lymphadenopathy. Systemic adverse events include fatigue, headache, fever, chills, nausea and vomiting. The Pfizer vaccine was associated with four cases of severe adverse events, including shoulder injury related to vaccine administration, right axillary lymphadenopathy, paroxysmal ventricular arrhythmia, and right leg paresthesia. Three cases of transverse myelitis (TM) and one case of multiple sclerosis (MS) were associated with Oxford-AstraZeneca vaccine, in response to which, the study was placed on temporary hold for careful independent review of each case. It was determined that only 1 case of TM in the vaccine group was a vaccine-related adverse event, while the remaining 2 cases of TM—one in the vaccine group, the other in placebo group—were unrelated to the vaccine. Further independent investigation revealed that the patient in the vaccine group who developed MS 10 days after receiving the first dose had pre-existing, underlying, unrecognized MS; thus, this case was also found to be unrelated to the vaccine.

Pfizer/BioNTech reported six deaths during their study, two from the vaccine group and four from the placebo group. However, the investigators concluded that these deaths were not related to the vaccine or to the placebo. Gamaleya investigators reported three deaths during the study, but none of these was reported to be associated with the vaccine. Johnson & Johnson also reported three deaths that were not related to the study. Oxford-AstraZeneca reported five deaths, one in the vaccine group and four in the placebo group. The death in the vaccine group was deemed unrelated to the vaccine or to COVID-19, while in the placebo group, there was one death due to severe COVID-19 leading to hospitalization 21 days after the first placebo dose. The remaining three deaths in the placebo group were unrelated to COVID-19 or to the vaccine.

Vaccine efficacy and SARS-CoV-2 variants

Data on the potential efficacy of four vaccines against new SARS-CoV-2 variants, as well as the origins of the variants and the locations of their mutations, are described in Table 3. There are currently no available data on the impact of the new COVID-19 variants on the severity of the disease, but the UK variant (B.1.1.7) and Brazil variant (P.1) have been found to be more transmissible than the original SARS-CoV-2 virus. In a recent study, the Pfizer/BioNTech vaccine demonstrated poor efficacy against the South Africa variant (B.1.351).

Discussion

Here, we reviewed the available data on the 10 vaccines that have—as of March 1, 2021—reached phase III of the clinical development process. Data from peer-reviewed publications are available for only four vaccines. The existing evidence concerning vaccine efficacy and safety is encouraging, but we still do not have data on vaccine effectiveness and possible long-term complications. As more vaccines come into the market, it will be important to define which vaccines will be the most effective in preventing COVID-19, as well as achieving herd immunity.

The existing data on vaccine efficacy against the emerging SARS-CoV-2 variants are very limited. Only four vaccines (Pfizer/BioNTech, Novavax, Johnson & Johnson, and Bharat Biotech) have demonstrated efficacy against these variants; in the cases of Pfizer/BioNTech and Novavax, these effects have only been documented in vitro. No data are available on the efficacy of any vaccine against the California variant (CAL.20C). Future research should appraise COVID-19 vaccines on the basis of variant coverage. With an increasingly broad range of vaccines available, the potential risks and benefits of combining different vaccines also require study.
Table 1. Vaccines with peer-reviewed data.

| Vaccine Type | Participants | COVID-19 Cases | Efficacy (95% CI) | Phase III Trial Site | No. of doses (days apart) |
|--------------|--------------|----------------|-------------------|----------------------|----------------------------|
| Enrolled     | Vaccine      | Placebo        |                   |                      |                            |
| Mod-NIH RNA  | 30,420       | 15,210         | 15,210            | 196                  | 94.1 (89.3–96.8) USA       | 2 (28)                     |
| Pf-BNT RNA   | 43,448       | 21,720         | 21,728            | 170                  | 94.6 (89.9–97.3) USA, Germany, Turkey, Africa, Brazil, Argentina | 2 (21)                     |
| Oxf-Ast Viral vector | 23,848 | 12,082 | 11,766 | 131 | 70.4 (54.8–80.6) UK, South Africa, Brazil | 2 (28)                     |
| Gamaleya Viral vector | 21,977 | 16,501 | 5,476 | 78 | 91.6 (85.6–95.2) Russia | 2 (21)                     |

MOD-NIH: mRNA-1273, developed by Moderna and the National Institutes of Health.[2] Pf-BNT: BNT162b2, developed by Pfizer and BioNTech.[3] Oxf-Ast: Covishield/ChAdOx1 nCoV-19 (AZD1222), developed by Oxford University and AstraZeneca.[4, 5] Gamaleya: Sputnik V/Gam-COVID-Vac, developed by the Gamaleya Research Institute.[6, 7]

Table 2. Vaccines with press release data.

| Vaccine Type | Participants | COVID-19 Cases | Efficacy (95% CI) | Phase III Trial Site | No. of doses |
|--------------|--------------|----------------|-------------------|----------------------|-------------|
| Enrolled     | Vaccine      | Placebo        |                   |                      |             |
| J & J Viral vector | 44,325 | 19,866 | NA | 469 | 66% (NA) USA, Argentina, Brazil, Chile, Colombia, Mexico, Peru, South Africa | 1            |
| Nov-HHS Recombinant spike protein nanoparticle | 15,000 | NA | NA | 62 (6:56)† | 89.3% (75.2–95.4) UK | 2            |
| BB-NIV Whole-virion inactivated | 25,800 | NA | NA | NA | NA India | 2            |

J & J: Ad26.COV2-S, developed by Johnson & Johnson.[8, 9] Nov-HHS: NVX-CoV2373, developed by Novavax and the Department of Health and Human Services.[10–11] BB-NIV: Covaxin/BBV152, developed by Bharat Biotech and the National Institute of Virology.[12] †Phase 2b. Total (vaccine:placebo)

Table 3. SARS-CoV-2 variants.

| Name       | Origin   | Location of Mutations | First Reported | First Reported (US) | Vaccine Effectiveness |
|------------|----------|-----------------------|----------------|---------------------|----------------------|
| B.1.1.7    | UK       | Mutation in RBD* of spike protein at position 501: amino acid asparagine (N) replaced with tyrosine (Y); P618H replacement on the spike proteins. Deletion at positions 69 and 70 of spike protein. | UK, September 2020 | December 2020 | Pfizer/BioNTech (in vitro studies) [14] Novavax (NVX-CoV2373) 89.3% efficacy [10] Covaxin/BBV152 Bharat Biotech (in vitro studies) [15] |
| B.1.351    | South Africa | Eight lineage-defining mutations in the spike protein. Spike protein, including K417N, E484K, N501Y | South Africa, October 2020 | January 2021 | Pfizer/BioNTech (in vitro studies) [14] Janssen (Phase III trial, 95% S.A. population) [8, 9] Novavax (NVX-CoV2373) 60% efficacy [10] Moderna (mRNA-1273) [17] |
| P.1        | Brazil   | 17 unique mutations, including 3 in RBD of spike protein | Japan, January 2021 | January 2021 | Janssen [8, 9] Novavax (NVX-CoV2373) |
| CAL.20C    | USA (Southern CA) | Cluster 20C consists of 5 mutations: ORF1a: I4205V, ORF1b: D1183Y, S: S13I; W152C; L452R (S13I and W152C in the N-terminal domain, and L452R in RBD) | Los Angeles (CA), July 2020 | July 2020 | Unknown |

*Receptor binding domain †The shorthand for this mutation is N501Y
Received: March 3, 2021  
Accepted: March 3, 2021  
Published: March 3, 2021  

Copyright: © 2021 The author(s). This original article is brought to you for free and open access by ThinkIR: The University of Louisville's Institutional Repository. For more information, please contact thinkir@louisville.edu. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding Source: The author(s) received no specific funding for this study.

Conflict of Interest: All authors declared no conflict of interest in relation to the main objective of this work.

References

1. Draft landscape and tracker of COVID-19 candidate vaccines. 2021. Available at: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines. Accessed 15 February 2021.

2. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2020; 384:403–416. doi: 10.1056/NEJMoa2035389. PMID: 33378609.

3. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med 2020; 383:2603–2615. doi: 10.1056/NEJMoa2034577. PMID: 3301246.

4. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021; 397:99–111.

5. Voysey M, Costa Clemens SA, Madhi SA, et al. Single dose administration, and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine. SSRN [Preprint]. 2021 doi: 10.2139/ssrn.3777268.

6. Logunov DY, Dolzhikova IV, Scheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 2021; 397:671–681. doi: 10.1016/S0140-6736(21)00234-8. PMID: 33545094.

7. Jones I, Roy P, Sputnik V COVID-19 vaccine candidate appears safe and effective. Lancet 2021; 397:642–643. doi: 10.1016/S0140-6736(21)00191-4. PMID: 33545098.

8. Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial. 2021. Available at: https://www.jnj.com/johnson-johnson-covid-19-vaccine-authorized-by-u-s-fda-for-emergency-use-first-single-shot-vaccine-in-fight-against-global-pandemic. Accessed 15 February 2021.

9. Janssen Investigational COVID-19 Vaccine: Interim Analysis of Phase 3 Clinical Data Released. Available at: https://www.nih.gov/news-events/news-releases/janssen-investigational-covid-19-vaccine-interim-analysis-phase-3-clinical-data-released. Accessed 15 February 2021.

10. Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial. 2021. Available at: https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3. Accessed 14 March 2021.

11. Novavax Announces Start of Rolling Review by Multiple Regulatory Authorities for COVID-19 Vaccine Authorization. 2021. Available at: https://ir.novavax.com/news-releases/news-release-details/novavax-announces-start-rolling-review-multiple-regulatory. Accessed 14 March 2021.

12. COVAXIN®- India’s First Indigenous Covid-19 Vaccine. 2021. Available at: https://www.bharatbiotech.com/covaxin.html. Accessed 15 February 2021.

13. Science Brief: Emerging SARS-CoV-2 Variants. 2021. Available at: https://www.cdc.gov/coronavirus/2019-ncov/more/science-and-research/scientific-brief-emerging-variants.html. Accessed 15 February 2021.

14. Pfizer and BioNTech Publish Results of Study Showing COVID-19 Vaccine Elicits Antibodies that Neutralize Pseudovirus Bearing the SARS-CoV-2 U.K. Strain Spike Protein in Cell Culture. 2021. Available at: https://www.pfizer.com/. Accessed 15 February 2021.

15. Sapkal GN, Yadav PD, Ella R, et al. Neutralization of UK-variant VUI-202012/01 with COVAXIN vaccinated human serum. bioRxiv [Preprint]. 2021 doi: 10.1101/2021.01.26.426986.

16. Zhang W, Davis BD, Chen SS, Sincuir Martinez JM, Plummer JT, Vail E. Emergence of a novel SARS-CoV-2 variant in southern California. JAMA 2021. Online ahead of print. doi: 10.1001/jama.2021.1612.

17. Wu K, Werner AP, Moliva JI, et al. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. bioRxiv [Preprint]. 2021 doi: 10.1101/2021.01.25.427948. PMID: 33501442.

18. Liu Y, Liu J, Xia H, et al. Neutralizing activity of BNT162b2-elicited serum—preliminary report. N Engl J Med 2021. Online ahead of print. doi: 10.1056/NEJMc2102017.